---
layout: default
title: Palbociclib
parent: Model Prediction Only (L5)
nav_order: 693
evidence_level: L5
indication_count: 10
---

# Palbociclib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Palbociclib: From Breast Cancer to Hyperthyroidism

## One-Sentence Summary

Palbociclib is a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer. The Canadian license records in the Evidence Pack do not state the approved indication, so breast cancer is inferred from the trial and literature context. The TxGNN model predicts it may be effective for **hyperthyroidism**, but **no clinical trials and no publications** currently support this prediction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Breast cancer (HR+/HER2-), inferred from trial and literature context; not stated in the Canadian license records |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 9 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known information, palbociclib is a CDK4/6 inhibitor that blocks cell-cycle progression, and its efficacy in breast cancer is established.

Nothing in the provided data links CDK4/6 inhibition to thyroid hormone synthesis or secretion. The high score (99.44%) is a model prediction only, and the same thyroid-related cluster appears in other low-evidence predictions (resistance to thyroid hormone, hyperthyroxinemia). At present this prediction should be treated as a model artefact rather than a credible repurposing lead.

For comparison, the second-ranked prediction, **rheumatoid arthritis**, has more support: one case report, preclinical CDK6-dependent synovial hyperplasia data and animal-model work. It is graded L4, still a research question, but it is a better candidate for follow-up than hyperthyroidism.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

Nine licenses are on record. The five main ones are listed below. Dosage form and approved-indication text are not recorded in the source data.

| DIN | Product Name |
|---------|------|
| 2547643 | TARO-PALBOCICLIB |
| 2552140 | PMS-PALBOCICLIB |
| 2552132 | PMS-PALBOCICLIB |
| 2547635 | TARO-PALBOCICLIB |
| 2552124 | PMS-PALBOCICLIB |

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | Bone marrow suppression is a recognised common adverse event of CDK4/6 inhibitors in the literature provided |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count (with differential) |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

- **Drug Interactions**: No interaction records were found in the queried database.
- **Class-level signals from the literature**: Pharmacovigilance analyses report thromboembolic events and interstitial lung disease with CDK4/6 inhibitors. Bone marrow suppression and gastrointestinal toxicity are also common.

Please refer to the package insert for full warnings and contraindications.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on model score alone (L5), with no trials, no publications and no plausible mechanistic link between CDK4/6 inhibition and hyperthyroidism. The drug also carries known myelosuppression risk, which is hard to justify in a benign endocrine condition without supporting evidence.

**To proceed, the following is needed:**
- Mechanism of action data from DrugBank
- Health Canada package insert warnings and contraindications
- Any preclinical or clinical data linking CDK4/6 inhibition to thyroid hormone excess
- Consideration of rheumatoid arthritis (rank 2, L4) as a more evidence-supported repurposing question
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

